Policy & Regulation

Ozempic Is Now Generic in India — And Novo Nordisk Just Cut Prices 48%. The Obesity Drug War Has Begun.

By BHC, Editor in Chief · April 02, 2026 · 5 min read

BHC, Editor in Chief — Ozempic Is Now Generic in India — And Novo Nordisk Just Cut Prices 48%. The Obesity Drug War Has Begun.

Summary

  • Semaglutide's India patent expired on March 20, 2026. Generics launched immediately, prices dropped 90%, and Novo Nordisk has now cut branded prices by up to 48%. Here is a complete guide to what changed and what it means.

On the morning of March 21, 2026, something historic happened in Indian healthcare. The day before, semaglutide — the active molecule in Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss drug Wegovy — lost its patent protection in India. Within 24 hours, more than a dozen domestic pharmaceutical companies launched cheaper generic versions.

"What we understand is there will be more than 50 brands launching in India. More than 40 players are entering this market. The price drop is real and the scale will be massive."

By evening, a drug that had cost patients ₹10,000 or more per month was available for under ₹2,000. For 135 million Indians living with diabetes — the largest absolute burden globally — and an estimated 250 to 350 million living with overweight or obesity, this is not just a business story. It is a public health turning point.

**The Scale of What Just Happened

The speed and scale of the Indian generic launch is without precedent in recent pharma history. Sun Pharma launched under the brand names Noveltreat and Sematrinity. Zydus Lifesciences entered with Semaglyn and Mashema. Dr Reddy's, Alkem, Glenmark, and Natco Pharma all announced their own versions, with more than 40 manufacturers in total expected to launch brands. Pharmarack analysts estimate the final market will feature over 50 competing semaglutide brands. India's weight-loss drug market, which had grown tenfold in five years to $153 million as of 2026, is now projected to soar past $500 million by 2030. Investment bank Jefferies projects the Indian semaglutide market could eventually reach $1 billion at the right price points.

Novo Nordisk, facing this competitive onslaught, responded within days. The Danish pharmaceutical giant announced price cuts of up to 48% on Wegovy and 36% on Ozempic's starting doses, with average reductions across full treatment courses of 27% and 24% respectively. Vikrant Shrotriya, Managing Director of Novo Nordisk India, confirmed the cuts in a statement, acknowledging the new pricing reality created by generic entry.

**What Generic Semaglutide Actually Costs Now

The price landscape is still settling, but early data gives a picture. Some generic versions are being offered below ₹2,000 per month for starting doses — a drop of as much as 90% from earlier branded prices. Industry analysts expect the market to stabilise around ₹3,500 to ₹4,000 per month for starting doses of quality-assured generic versions. That is still a dramatic reduction from the pre-generic baseline and significantly expands the addressable patient population.

**What Doctors Need to Know

The clinical excitement around semaglutide is well-founded. The drug mimics a gut hormone called GLP-1, reducing appetite and slowing digestion, leading to meaningful weight loss and improved blood sugar control. But generic availability does not automatically mean appropriate access. Several important clinical considerations apply specifically to Indian patients.

Critically, the BMI thresholds used internationally to determine eligibility for semaglutide were developed based on data from predominantly Western populations. South Asians face significantly greater cardiometabolic risk at lower BMI values than Europeans or Americans — Indian patients can develop serious metabolic disease at BMI levels that would be considered normal in the West. This means the eligibility criteria need active recalibration for the Indian context, something the medical community is already debating.

Side effects — including nausea, gastrointestinal disturbance, and in rare cases identified by regulators, a risk of vision changes — require clinical monitoring. Semaglutide is most effective as part of a managed care programme, not as a standalone prescription. Dr. Atul Luthra, an endocrinologist at Fortis Hospital, has noted that regular physical activity and proper diet are essential companions to the medication, not optional extras.

**The Global Ripple Effect

India supplies more than half of Africa's generic medicines. Cheaper Indian generic semaglutide will not stay within India's borders. Dr Reddy's is already planning to launch its generic version in Canada by May 2026, and has outlined plans to enter 87 countries. For middle-income countries where obesity and diabetes rates are rising rapidly but branded semaglutide has been completely unaffordable, Indian generics represent a genuine access breakthrough.

**BHC Perspective

For the Bengaluru Health Community ecosystem, this is a story with multiple layers. For startup founders in metabolic health, diabetes management, and obesity care — the generic semaglutide wave creates a dramatically expanded patient population that will need structured clinical support, not just a pill. For hospital networks and outpatient care operators, expect a surge in patients seeking GLP-1 therapy who will need monitoring, dose titration, and lifestyle support. For pharma entrepreneurs and investors — the semaglutide market is now a volume and brand-differentiation game, where quality assurance, cold chain reliability, and physician trust will determine winners. The patent wall has fallen. What happens next is a story of execution.

**Frequently Asked Questions

Q: What is semaglutide and why does its patent expiry matter?
A: Semaglutide is the active molecule in Novo Nordisk's Ozempic (diabetes) and Wegovy (obesity) drugs. Its India patent expired on March 20, 2026, immediately allowing Indian generic manufacturers to launch cheaper versions and dropping prices by up to 90%.

Q: Which Indian companies have launched generic semaglutide?
A: Sun Pharma, Zydus Lifesciences, Dr Reddy's Laboratories, Alkem, Glenmark, and Natco Pharma are among the first movers. More than 40 manufacturers are expected to enter the market, creating over 50 competing brands.

Q: How much does generic semaglutide cost in India now?
A: Early generic versions are being offered below ₹2,000 per month for starting doses — a reduction of up to 90% from earlier branded prices of ₹10,000+ per month. Novo Nordisk has also cut branded Wegovy prices by 48% in response.